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Abstract
Background: The small intestine is extremely sensitive to ischemia-reperfusion (I/R) injury and a
range of microcirculatory disturbances which contribute to tissue damage. Previous studies have
shown that leptin plays an important physiological role in the microvasculature. The aim of this
study was to evaluate the protective effects of leptin in I/R – induced mucosal injury in the small
intestine.
Methods: Forty rats were divided into 5 groups (n = 8). Group I was subjected to a sham
operation. Following mesenteric ischemia in group II (control); physiologic saline 1 cm3, in group
III; leptin 100 µg/kg, and physiologic saline 1 cm3, in group IV; NG-L-arginine methyl ester (L-NAME)
20 mg/kg, and physiologic saline 1 cm3, in group V; leptin 100 µg/kg, L-NAME 20 mg/kg, and
physiologic saline 1 cm3 were given intra-peritoneally. In these groups, an I/R procedure was
performed by occlusion of the superior mesenteric artery for 45 min followed by 120 min
reperfusion. After reperfusion, the small intestines were resected for malondialdehyde (MDA) and
nitric oxide (NO) concentration and histopathologic properties. Mucosal lesions were scored
between 0 and 5. Tissue MDA and NO concentration and histopathologic grades were compared
statistically.
Results: Tissue MDA level significantly increased (P < 0.05), tissue NO level significantly decreased
in group V animals, compared to group III animals respectively (P < 0.001). Histopathologically,
intestinal injury significantly decreased in the leptin treated ischemic group.
Conclusion: Leptin can be used safely in mesenteric occlusive diseases, since it induces NO
formation and release in mesenteric vessels.
Background
I/R injury is a phenomenon often confronted in surgical
pathologies and it is quite important because it causes
severe clinical pathologies by causing destruction in close
and far tissues. A mean effect of the I/R injury is formed at
the reperfusion phase, and free oxygen radicals that
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appear in the reoxygenized tissue are held responsible for
this mechanism [1,2]. NO, recently purported to be
endothelium-derivated relaxing factor, reacts with super-
oxide in pathogical states and might form cytotoxic spe-
cies including peroxynitrite anion and hydroxyl radical
[3]. Generation of the hydroxyl radical could be responsi-
ble for some of the injury associated with I/R and other
oxidant-mediated disease states [4]. In animal models of
I/R injury, administration of nitric oxide synthase (NOS)
inhibitors (L-NAME) has been shown to exacerbate intes-
tinal impairment [5]. Furthermore, NO supplementation
ameliorates structural and functional damage accompa-
nying experimental I/R [6]. Presently three NOS isoforms,
namely NOS-I (neuronal), NOS-II (inducible) and NOS-
III (endothelial), have been identified as being responsi-
ble for NO formation [7]. NOS-III is the predominant iso-
form in the gastrointestinal tract [8].
Leptin, a circulating hormone secreted by adipocytes,
influences body weight homeostasis through effects on
food intake and energy expenditure [9,10]. Invitro studies
showed that leptin has the potency to mediate mitogenic
effects on endothelial cells [11-13], monocytes [14], respi-
ratory epithelial cells [15], glomerular endothelial cells
[16], adrenal cells [17] and colonic epithelial cells [18].
Moreover, leptin accelerates the healing of colonic anasto-
moses [19]. Recently, it has been reported that the func-
tional leptin receptor OB-Rb is expressed in endothelial
cells and it is functionally competent [20]. This provides
evidence that the endothelium is a target for leptin action
[21]. Previous studies showed that leptin controls the
release of NO by activating NOS [22].
We hypothesize that leptin stimulates NO production and
release from the small intestine mesenteric endothelium.
L-NAME and leptin were used, and tissue MDA, NO levels
were measured.
The aim of this study was to assess the possibility of leptin
treatment in the mesenteric occlusive diseases and to
investigate the relationship between leptin and NO in
intestinal I/R injury in Wistar rats.
Methods
All experiments were performed in the Surgical Research
Center at Osmangazi University. The University Ethics
Committee approved this study. Adult male Wistar rats
weighting 200 and 250 g housed in a cage were given
standard rat feed with free access to water. Rats were anes-
thetized with thiopentone sodium (Pental, Bayer) and
heparinized with sodium heparin (Nevparin, Mustafa
Nevzat) intraperitoneally after a 12-h starvation period.
After the abdominal wall was cleansed with 10% povi-
done-iodine (Betadine, Seton), laparatomy was per-
formed by a midline incision. All rats were divided into
five groups.
Group I (n = 8); sham operated group
Group II (n = 8); I/R group: following 45 min mesenteric
ischemia, given 1 cm3 physiologic saline intraperitoneally
Group III (n = 8); I/R+Leptin group: following 45 min
mesenteric ischemia, given 100 µg/kg leptin, and 1 cm3
physiologic saline intraperitoneally
Group IV (n = 8); I/R+L-NAME group: following 45 min
mesenteric ischemia, given 20 mg/kg L-NAME, and 1 cm3
physiologic saline intraperitoneally
Group V (n = 8); I/R+Leptin+L-NAME group: following 45
min mesenteric ischemia, given 100 µg/kg leptin, 20 mg/
kg L-NAME, and 1 cm3 physiologic saline intraperito-
neally
Mesenteric ischemia was performed in groups II-V. Small
intestine was subjected to 45 min of ischemia achieved by
occluding of superior mesenteric artery with a vascular
clamp, and at the end of the ischemia, 120 min reper-
fusion was performed.
100 µg/kg of Leptin (Sigma-Aldrich, Germany) was given
intraperitoneally as defined previously [23] at the end of
the mesenteric ischemia in groups III, V. The aim of leptin
administration at the end of ischemia, was to assess the
treatment properties of this hormone on reperfusion
injury.
L-NAME (Sigma-St.Louis, USA) was given 20 mg/kg intra-
peritoneally as defined previously [23] at the end of the
mesenteric ischemia in groups IV, V.
After occlusion of superior mesenteric artery with a vascu-
lar clamp, the laparotomy incision was closed continu-
ously with 3/0 silk (Silk, Ethicon, UK) sutures in all
groups. The rats were placed in their cages. 45 min after
their operation, relaparotomy was performed following
the same anaesthesia protocol and vascular clamp was
removed. 120 min reperfusion was performed and reper-
fusion of the mesenteric vasculature was confirmed by the
return of pulsation of the vascular arcade.
The entire small intestine was carefully removed and
placed on ice. The small intestine was divided into two
equal segments: the proximal (jejunum) and distal
(ileum). Each segment was rinsed thoroughly with physi-
ologic saline and opened longitudinally to expose the
intestinal epithelium. The jejunum segment was sepa-
rated into two equal pieces, and one of them was used toBMC Gastroenterology 2005, 5:37 http://www.biomedcentral.com/1471-230X/5/37
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determine the tissue MDA and NO concentration, and
was immediately placed in deep freezer at -70°C.
Determination of MDA
Freezed intestinal tissue was homogenized 1:10 in 1.15%
KCI, and MDA levels were determined according to tio-
barbituric acid method [24]. Results were expressed as
nmol MDA/mg protein.
Determination of NO
Nitrate in tissue was assayed by a modification of the cad-
mium-reduction method as Cortas et al. defined [25]. The
nitrite produced was determined by diazotization of sul-
phanylamide and coupling to naphthylethylene diamine.
After samples were deproteinized with Somogyi reagent,
the nitrate was reduced by Cu-coated Cd in glycine buffer
at pH 9.7 (2.5 to 3 g of Cd granules for a 4 ml reaction
mixture). The reduction followed pseudo-first-order reac-
tion kinetics, a convenient time interval for assay being 90
min. Maximum reduction occurred at about 2 h. Results
were expressed as pmol/mg protein.
Histopathologic examination
Ileum segments were placed in 10% formalin solution.
Paraffin blocks were prepared from the tissue pieces and
were kept in 10% formalin solution. The sections with 4.5
micron thickness were painted with Haematoxylin-Eosin
(HE). Light microscopic studies were reviewed by a
pathologist blinded to protocol. The degree of intestinal
tissue injury was evaluated and each was graded from 0 to
5, identical to that originally described by Chiu et al [26].
Grade 0 was defined as normal mucosa and grade 1 was
the development of a subepithelial space at the tips of the
villi. This space was more extended in grade 2. And in
grade 3 there was a massive epithelial lifting down the
sides of the villi. In grade 4, the villi were denuded of epi-
thelium and in grade 5; it was characterized by a loss of
the villi themselves.
Statistical analysis
Data was presented as mean ± standard derivation (SD).
One-way analysis of variance (ANOVA) and Tukey Post
Hoc (parametric) test was used to compare tissue MDA
and NO levels between the groups. Histopathologic
grades of the groups were compared with Kruskal-Wallis
test and Tukey Post Hoc (nonparametric) test. The differ-
ences were considered significant at P < 0.05.
Results
Evaluation of mesenteric ischemia
Tissue MDA and NO levels significantly increased in I/R
group animals, compared to sham operated group animals
(MDA: 3.76 ± 0.17 vs. 2.54 ± 0.09 nmol/mg, P < 0.05;
NO: 201.00 ± 11.59 vs. 126.75 ± 12.38 pmol/mg, P <
0.05) (Table 1). On histopathological analysis, intestinal
tissue injury significantly increased in I/R group(Figure 2)
animals, compared to sham operated group(Figure 1) ani-
mals (Jejunum: 3.45 ± 0.17 vs. 0.00 ± 0.08, χ2 = 28,63 df
= 4 P < 0.001; ileum: 3.73 ± 0.13 vs. 0.00 ± 0.00, χ2 =
28,63 df = 4 P < 0.001) (Table 2).
Effects of leptin on mesenteric ischemia
Tissue MDA level significantly decreased in I/R+Leptin
group  animals, compared to I/R group animals (MDA:
2.80 ± 0.18 vs. 3.76 ± 0.17 nmol/mg, P < 0.05), but tissue
NO level significantly increased in I/R+Leptin group ani-
mals, compared to I/R group animals (NO: 345.38 ±
22.29 vs. 201.00 ± 11.59 pmol/mg, P < 0.001). On his-
topathological analysis, intestinal tissue injury signifi-
cantly decreased in jejunum in I/R+Leptin group (Figure 3)
animals, compared to I/R group animals (2.71 ± 0.08 vs.
Intestinal villus after I/R in group II rats Figure 2
Intestinal villus after I/R in group II rats. Note lifted epithe-
lium, white blood cells, and monocytes in the Lamina propria 
(Grade IV) (HE, ×100).
Normal intestinal mucosa in group I rats (Grade 0) (HE,  ×100) Figure 1
Normal intestinal mucosa in group I rats (Grade 0) (HE, 
×100).BMC Gastroenterology 2005, 5:37 http://www.biomedcentral.com/1471-230X/5/37
Page 4 of 7
(page number not for citation purposes)
3.45 ± 0.17, χ2 = 28,63 df = 4 P < 0.05). However, there
was no significant difference in intestinal injury in ileum
between I/R+Leptin group and I/R group animals (Table
2).
Effect of L-NAME on mesenteric ischemia
Tissue MDA level increased in I/R+L-NAME group ani-
mals compared to I/R group animals (MDA: 3.88 ± 0.22
vs. 3.76 ± 0.17 nmol/mg, P > 0.05), but tissue NO level
significantly decreased in I/R+L-NAME group animals,
compared to I/R group animals (NO: 140.25 ± 8.81 vs.
201.00 ± 11.59 pmol/mg, P < 0.05). On histopathological
analysis, there was no significant difference in intestinal
injury between I/R+L-NAME group (Figure 4) and I/R
group animals (Table 2).
Effects of leptin and L-NAME on mesenteric ischemia
Tissue MDA level significantly increased in I/R+Leptin+L-
NAME group animals, compared to I/R+Leptin group ani-
mals (MDA: 3.74 ± 0.20 vs. 2.80 ± 0.18 nmol/mg, P <
0.05) there was no significant difference in tissue MDA
levels between I/R+Leptin+L-NAME group and  I/R+L-
NAME group. Tissue NO level significantly decreased in I/
R+Leptin+L-NAME group animals, compared to I/R+Lep-
tin group animals (NO: 183.50 ± 14.63 vs. 345.38 ± 22.29
pmol/mg, P < 0.001), but there was no significant differ-
ence in tissue NO level between I/R+Leptin+L-NAME
group and I/R+L-NAME group. On histopathological anal-
ysis, intestinal tissue injury significantly increased in I/
R+Leptin+L-NAME group (Figure 5) animals, compared to
I/R+Leptin group animals (Jejunum: 3.44 ± 0.20 vs. 2.71 ±
0.08, χ2 = 28,63 df = 4 P < 0.05; ileum: 3.63 ± 0.14 vs. 2.88
± 0.20, χ2 = 28,63 df = 4 P < 0.05). However, there was no
significant difference in intestinal injury between I/R+Lep-
tin+L-NAME group and  I/R+L-NAME group animals
(Table 2).
Discussion
Syndromes of mesenteric ischemia remain clinically chal-
lenging, despite decades of surgical experience. The causes
of mesenteric ischemia are well known and its major com-
plication, gangrenous necrosis of portions of the gastroin-
testinal tract, is well recognized by all surgeons.
Nevertheless, diagnosis and effective treatment is often
delayed in these patients, and when gut infarction occurs,
the mortality rates range from 50% to 80%, making
mesenteric ischemia one of our most lethal vascular prob-
lems [27]. Ischemia and consecutive reperfusion causes
oxidative stress, which is characterized by an imbalance
between reactive oxygen species (ROS) and the anti-oxi-
dative defence system. Reperfusion of ischemic tissue,
although necessary for a reparative mechanism, has been
shown to worsen acute ischemic injury via the release of
ROS [28]. I/R injury to the small intestine causes local
production of the ROS which are known to play an impor-
tant role in gut epithelial damage [29]. Increased lipid per-
oxidation in lung, liver and small intestine in animals
with intestinal I/R, was evidenced by significantly
increased MDA levels in all three organs. This previously
has been demonstrated in different studies with signifi-
cantly increased MDA levels in lung [30] and intestine,
induced by intestinal I/R [31]. Recent evidence has sug-
Table 1: Effects of leptin on tissue MDA and NO levels




I2 . 5 4  ±  0 . 0 9
II 3.76 ± 0.17 *
III 2.80 ± 0.18 *
IV 3.88 ± 0.22 * *
V3 . 7 4  ±  0 . 2 0 * *
Tissue NO 
(pmol/mg protein)
I 126.75 ± 12.38
II 201.00 ± 11.59 *
III 345.38 ± 22.29 * *
IV 140.25 ± 8.81 * *
V 183.50 ± 14.63 *
* P < 0.05
Tissue MDA: F(4:35) = 12,60 P < 0.001; ANOVA. P < 0.05; Tukey Post 
Hoc (parametric) Test
Tissue NO: F4:35 = 35,25 P < 0.001; ANOVA. P < 0.05; Tukey Post 
Hoc (parametric) Test
Table 2: Intestinal injury scores in groups




I0 . 0 0 ±  0 . 0 8
II 3.45± 0.17 *
III 2.71± 0.08 * *
IV 3.71± 0.16 * *
V3 . 4 4 ±  0 . 2 0 * *
Ileum (Median score)
I0 . 0 0 ±  0 . 0 0
II 3.73± 0.13 *
III 2.88± 0.20 *
IV 3.94± 0.18 * *
V3 . 6 3 ±  0 . 1 4 * *
* P < 0.05
Jejunum: χ2 = 28,63 df = 4, P < 0.001; Kruskal-Wallis Test. P < 0.05; 
Tukey Post Hoc (nonparametric) Test
Ileum: χ2 = 25,88 df = 4, P < 0.001; Kruskal-Wallis Test. P < 0.05; 
Tukey Post Hoc (nonparametric) TestBMC Gastroenterology 2005, 5:37 http://www.biomedcentral.com/1471-230X/5/37
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gested that NO may play a significant role in the mainte-
nance of mucosal integrity. In the mesenteric
endothelium, low levels of continuous release of NO by
NOS III, is thought to be a major determinant of vascular
tone and regulator of blood flow of the mucosa [32]. In
the present study, 45 min of mesenteric ischemia was
achieved by the occlusion of superior mesenteric artery
with a vascular clamp and 120 min reperfusion was
regained after ischemia. This study also showed that, tis-
sue MDA and NO levels significantly increased in
ischemic groups. On a histopathological analysis, intesti-
nal tissue injury significantly increased in the ischemic
group, compared to the non-ischemic group.
Leptin, a circulating hormone secreted by adipocytes,
influences body weight homeostasis through effects on
food intake and energy expenditure [9,10]. Previous stud-
ies showed that leptin increases NO synthesis in a dose-
dependent manner in Wistar rats [33]. Kimura et al.
showed that leptin relaxes the rat mesenteric artery. The
vasodilatation of mesentery beds is mediated by endothe-
lium-derivated NO [34]. It is well known that NO is pro-
duced by NOS in endothelial cells [35]. It relaxes vessels
by stimulating guanylate cyclase in underlying smooth
muscle cells [36]. In our study, tissue MDA level signifi-
cantly decreased in leptin-treated ischemic group, com-
pared to the ischemic group, but tissue NO level
significantly increased in the leptin-treated ischemic
group, compared to the ischemic group. On histopatho-
logical analysis, intestinal tissue injury significantly
decreased in the leptin-treated ischemic group, compared
to the ischemic group. This results supports the findings of
Kimura et al.
In animal models of I/R injury, administration of NOS
inhibitors was shown that these exacerbate intestinal
impairment [5]. NO synthesis is inhibited by L-arginine
analogues, such as L-NAME [37]. In our study, tissue MDA
level increased in the L-NAME-administrated ischemic
group, compared to the ischemic group, but tissue NO
level significantly decreased in the L-NAME-administrated
ischemic group, compared to the ischemic group. On his-
topathological analysis, intestinal tissue injury increased
in the L-NAME-administrated ischemic group, compared
to the ischemic group.
Salzman et al showed that in the mesenteric endothelium,
low level continuous release of NO by NOS III is thought
to be a major determinant of vascular tone and regulator
of blood flow of the mucosa [32]; and previous studies
showed that leptin plays a major role in NO release by
activating NOS in the adipocytes and the adjacent capil-
lary endothelium [22]. Kimura et al showed that leptin
Villus necrosis involving >distal one-half villus involvement in  group V rats (Grade III) (HE, ×100) Figure 5
Villus necrosis involving >distal one-half villus involvement in 
group V rats (Grade III) (HE, ×100).
Mucosal ulceration, and necrosis with invasion of muscularis  propria in group IV rats (Grade V) (HE, ×100) Figure 4
Mucosal ulceration, and necrosis with invasion of muscularis 
propria in group IV rats (Grade V) (HE, ×100).
Development of Gruenhagen's space at tip of a villus in group  III rats (Grade II) (HE, ×100) Figure 3
Development of Gruenhagen's space at tip of a villus in group 
III rats (Grade II) (HE, ×100).BMC Gastroenterology 2005, 5:37 http://www.biomedcentral.com/1471-230X/5/37
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relaxes the rat mesenteric artery. The relaxation is medi-
ated by nitric oxide released from endothelium, and Cl(-)
plays an important role in leptin-induced nitric oxide
release [34]. In our study, tissue MDA level significantly
increased in the L-NAME-administrated, leptin-treated
group, compared to the leptin-treated group, but tissue
MDA level decreased in the leptin-treated group, com-
pared to the L-NAME-administrated group. Tissue NO
level significantly decreased in the L-NAME-adminis-
trated, leptin-treated group, compared to the leptin-
treated group, but increased in L-NAME-administrated,
leptin-treated group compared to L-NAME-administrated
group, but there was no statistical difference. On his-
topathological analysis, intestinal tissue injury signifi-
cantly increased in the L-NAME-administrated, leptin-
treated ischemic group, compared to the leptin-treated
ischemic group, but decreased compared to the L-NAME-
administrated ischemic group. This results indicates that
leptin was unable to increase the tissue NO levels in ani-
mals, subjected to NOS inhibition.
The leptin gene was isolated by Friedman's group,
through positional cloning from ob/ob mice that failed to
produce leptin and displayed extreme obesity and hyper-
phagia. There is high degree of homology in leptin from
different species [38]. Obesity in both rodents and
humans is generally associated with elevated leptin levels
[39]. Another form of mouse obesity, designated db/db,
demonstrates symptoms similar to those observed in ob/
ob mice, but the db/db mice failed to be rescued by leptin
administration. It was proposed that db/db mice might
have a mutation of the gene encoding the leptin receptor
[40]. The genes for both leptin and the leptin receptor
have been cloned and sequenced from the mouse, rat and
human, as well as from bovine, porcine and ovine tissues
[38]. In most human obesity cases [41], as well as in
model animals e.g. mice [42], obese individuals displayed
elevated plasma leptin levels compared to subjects of nor-
mal weight, thus demonstrating "leptin resistance". These
findings demonstrate that leptin plays an important role
in obesity and metabolic disorders, like diabetes.
Recently Lin et al. has reported that leptin has a time-
dependent response and orexin-A has a delayed response
to acute inflammatory stimuli such as intestinal I/R injury
and they may participate in metabolic disorders in injury
as inflammatory cytokines. In rats, subjected to 60 min-
utes of ischemia they found that, after 30 minutes of
reperfusion serum leptin levels decrease significantly and
after 360 minutes of reperfusion they increase signifi-
cantly; compared to the serum leptin levels before injury
and to sham-operated animals after injury [43]. On the
other hand, previously published studies demonstrate
that, at the onset of reperfusion tissue NO levels decrease
[44]. This study showed that the stimulatory effect of lep-
tin on NO synthesis and release significantly decreased
under NO synthesis inhibition by L-NAME.
Conclusion
This study envisages the possibility that leptin can be used
safely in mesenteric occlusive diseases, since it induces
NO production and release in mesenteric vessels.
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